Table of Contents
International Journal of Bacteriology
Volume 2016, Article ID 3535621, 10 pages
http://dx.doi.org/10.1155/2016/3535621
Review Article

A Review of Research Conducted with Probiotic E. coli Marketed as Symbioflor

Vermicon AG, Emmy-Noether Strasse 2, 80992 München, Germany

Received 22 April 2016; Accepted 25 October 2016

Academic Editor: Gary Dykes

Copyright © 2016 Claudia Beimfohr. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. A. Jacobi and P. Malfertheiner, “Escherichia coli nissle 1917 (Mutaflor): new insights into an old probiotic bacterium,” Digestive Diseases, vol. 29, no. 6, pp. 600–607, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Beutin, H. Seeliger, J. Winberg, D. van der Waaij, C. E. Nord, and W. Marget, “Oral administration of a certain strain of live Escherchia coli for intestinal disorders? Artificial contamination and manipulation of the digestive tract—our poor GIT!,” Infection, vol. 23, no. 1, pp. 51–54, 1995, Erratum: Infection, vol. 23, no. 4, pp. 245, 1995. View at Google Scholar
  3. H. Knothe, “The story of live human intestinal bacteria administered orally as a remedy,” Infection, vol. 23, no. 4, pp. 201–202, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Svandborg, “Comment to: oral administration of a certain strain of live Escherchia coli for intestinal disorders? Artificial contamination and manipulation of the digestive tract—our poor GIT!,” Infection, vol. 23, pp. 184–188, 1995. View at Google Scholar
  5. J. Schulze and U. Sonnenborn, “Comment to: oral administration of a certain strain of live Escherchia coli for intestinal disorders? Artificial contamination and manipulation of the digestive tract—our poor GIT!,” Infection, vol. 23, p. 251, 1995. View at Google Scholar
  6. U. Heyll and P. Wachauf, “‘Symbioselenkung’ oder ‘Mikrobiologische Therapie’—ein immunologisches Therapieprinziep?” Versicherungsmedizin, vol. 49, pp. 162–166, 1997. View at Google Scholar
  7. G. J. Jansen, A. C. M. Wildeboer-Veloo, D. van der Waaij, and J. E. Degener, “Escherichia coli as a probiotic?” Infection, vol. 26, no. 4, pp. 232–233, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Giese, K. Zimmermann, and S. C. Meuer, “Functional characterization of pro-biotic pharmaceuticals by quantitative analysis of gene expression,” Arzneimittel-Forschung, vol. 53, no. 5, pp. 385–391, 2003. View at Google Scholar · View at Scopus
  9. F. Courvoisier, V. Boutou, L. Guyon, M. Roth, H. Rabitz, and J.-P. Wolf, “Discriminating bacteria from other atmospheric particles using femtosecond molecular dynamics,” Journal of Photochemistry and Photobiology A: Chemistry, vol. 180, no. 3, pp. 300–306, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Courvoisier, L. Bonacina, V. Boutou et al., “Identification of biological microparticles using ultrafast depletion spectroscopy,” Faraday Discussions, vol. 137, pp. 37–49, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Willenbrock, P. F. Hallin, T. M. Wassenaar, and D. W. Ussery, “Characterization of probiotic Escherichia coli isolates with a novel pan-genome microarray,” Genome Biology, vol. 8, no. 12, article R267, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Magerl, V. Lammel, F. Siebenhaar, T. Zuberbier, M. Metz, and M. Maurer, “Non-pathogenic commensal Escherichia coli bacteria can inhibit degranulation of mast cells,” Experimental Dermatology, vol. 17, no. 5, pp. 427–435, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Möndel, B. O. Schroeder, K. Zimmermann et al., “Probiotic E. coli treatment mediates antimicrobial human β-defensin synthesis and fecal excretion in humans,” Mucosal Immunology, vol. 2, no. 2, pp. 166–172, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Reissbrodt, W. P. Hammes, F. dal Bello et al., “Inhibition of growth of Shiga toxin-producing Escherichia coli by nonpathogenic Escherichia coli,” FEMS Microbiology Letters, vol. 290, no. 1, pp. 62–69, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Enck, K. Zimmermann, G. Menke, and S. Klosterhalfen, “Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo,” Zeitschrift fur Gastroenterologie, vol. 47, no. 2, pp. 209–214, 2014, Erratum: Zeitschrift fur Gastroenterologie, vol. 52, no. 1, pp. 64, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. U. Martens, P. Enck, and E. Zieseniss, “Probiotic treatment of irritable bowel syndrome in children,” GMS German Medical Science, vol. 8, article Doc07, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. E. J. de Muinck, T. Øien, O. Storrø et al., “Diversity, transmission and persistence of Escherichia coli in a cohort of mothers and their infants,” Environmental Microbiology Reports, vol. 3, no. 3, pp. 352–359, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Gersemann, S. Becker, S. Nuding et al., “Olfactomedin-4 is a glycoprotein secreted into mucus in active IBD,” Journal of Crohn's and Colitis, vol. 6, no. 4, pp. 425–434, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Zschüttig, K. Zimmermann, J. Blom, A. Goesmann, C. Pöhlmann, and F. Gunzer, “Identification and characterization of microcin S, a new antibacterial peptide produced by probiotic Escherichia coli G3/10,” PLoS ONE, vol. 7, no. 3, Article ID e33351, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. P. D. Cotter, R. P. Ross, and C. Hill, “Bacteriocins—a viable alternative to antibiotics?” Nature Reviews Microbiology, vol. 11, no. 2, pp. 95–105, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. A. P. S. Hungin, C. Mulligan, B. Pot et al., “Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice—an evidence-based international guide,” Alimentary Pharmacology and Therapeutics, vol. 38, no. 8, pp. 864–886, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Pöhlmann, M. Thomas, S. Förster et al., “Improving health from the inside: use of engineered intestinal microorganisms as in situ cytokine delivery system.,” Bioengineered, vol. 4, no. 3, pp. 172–179, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Becker, T. A. Oelschlaeger, A. Wullaert et al., “Bacteria regulate intestinal epithelial cell differentiation factors both in vitro and in vivo,” PLoS ONE, vol. 8, no. 2, Article ID e55620, 2013, Erratum: PLoS ONE, vol. 85, 2013. View at Publisher · View at Google Scholar
  24. M. Caselli, F. Cassol, G. Calò, J. Holton, G. Zuliani, and A. Gasbarrini, “Actual concept of ‘probiotics’: is it more functional to science or business?” World Journal of Gastroenterology, vol. 19, no. 10, pp. 1527–1540, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Vitetta, D. Briskey, H. Alford, S. Hall, and S. Coulson, “Probiotics, prebiotics and the gastrointestinal tract in health and disease,” Inflammopharmacology, vol. 22, no. 3, pp. 135–154, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Enck, K. Zimmermann, G. Menke, S. Müller-Lissner, U. Martens, and S. Klosterhalfen, “A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome—a randomized controlled trial with primary care physicians,” Neurogastroenterology and Motility, vol. 20, no. 10, pp. 1103–1109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. A. C. Ford, E. M. M. Quigley, B. E. Lacy et al., “Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis,” The American Journal of Gastroenterology, vol. 109, no. 10, pp. 1547–1562, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. B. K. Sandhu and S. P. Paul, “Irritable bowel syndrome in children: pathogenesis, diagnosis and evidence-based treatment,” World Journal of Gastroenterology, vol. 20, no. 20, pp. 6013–6023, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Schumann, C. Alpert, W. Engst et al., “Mild gut inflammation modulates the proteome of intestinal Escherichia coli,” Environmental Microbiology, vol. 16, no. 9, pp. 2966–2979, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. T. M. Wassenaar, C. Beimfohr, T. Geske, and K. Zimmermann, “Voluntarily exposure to a single, high dose of probiotic Escherichia coli results in prolonged colonisation,” Beneficial Microbes, vol. 5, no. 4, pp. 367–375, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Szikszai, F. Lasitschka, T. Giese et al., “Standardization of a human organ culture model of intestinal inflammation and its application for drug testing,” Journal of Immunological Methods, vol. 421, pp. 96–103, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Zschüttig, C. Auerbach, S. Meltke et al., “Complete sequence of probiotic symbioflor 2 Escherichia coli strain G3/10 and draft sequences of symbioflor 2 E. coli strains G1/2, G4/9, G5, G6/7, and G8,” Genome Announcements, vol. 3, no. 2, p. e01330-14, 2015. View at Publisher · View at Google Scholar
  33. T. M. Wassenaar, A. Zschüttig, C. Beimfohr et al., “Virulence genes in a probiotic E. coli product with a recorded long history of safe use,” European Journal of Microbiology and Immunology, vol. 5, no. 1, pp. 81–93, 2015. View at Publisher · View at Google Scholar
  34. T. M. Wassenaar and F. Gunzer, “The prediction of virulence based on presence of virulence genes in E. coli may not always be accurate,” Gut Pathogens, vol. 7, article 15, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Didari, S. Mozaffari, S. Nikfar, and M. Abdollahi, “Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis,” World Journal of Gastroenterology, vol. 21, no. 10, pp. 3072–3084, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. N. Mazurak, E. Broelz, M. Storr, and P. Enck, “Probiotic therapy of the irritable bowel syndrome: why is the evidence still poor and what can be done about it?” Journal of Neurogastroenterology and Motility, vol. 21, no. 4, pp. 471–485, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Chichlowski and C. Rudolph, “Visceral pain and gastrointestinal microbiome,” Journal of Neurogastroenterology and Motility, vol. 21, no. 2, pp. 172–181, 2015. View at Publisher · View at Google Scholar · View at Scopus